Peiyu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peiyu Wang has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Yin Li
Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
12 shared publications Xianben Liu
Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
7 shared publicationsXiankai Chen
Department of Thoracic Surgical Oncology, National Cancer Center/Cancer Hospital
7 shared publications- Mantang Qiu
Department of Thoracic Surgery, Thoracic Oncology Institute, Peking University People’s Hospital, Beijing, China
6 shared publications Qi Liu
Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
6 shared publications- Xiangnan Li
Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University
5 shared publications
Latest Publications
- Open Access
Advocating for Precision Neoadjuvant and Subsequent Adjuvant Therapies in Esophageal Squamous Cell Carcinoma: Evidence From a Real‐World Multicenter Study
Controversies persist regarding the optimal regimens of neoadjuvant and adjuvant therapies for locally advanced esophageal squamous cell carcinoma (ESCC). This real‐world cohort study aimed to compare the efficacy of neoadjuvant chemotherapy (NCT), chemoradiotherapy (NCRT), and chemoimmunotherapy (NCIT), and to clarify the survival contributions of adjuvant strategies. We retrospectively enrolled 1818 ESCC patients across four high‐volume Chinese medical centers. After propensity score matching, pathological tumor response and tumor downstaging followed the hierarchy NCRT > NCIT > NCT, yet no significant differences were detected in overall survival (OS) or progression‐free survival (PFS). Subgroup analyses revealed superior OS benefits of NCIT in never‑smokers, nondrinkers, and patients with clinical N2–3 disease compared with NCT. While NCRT showed greater PFS benefit than NCIT as clinical T stage advanced, its OS advantage was restricted to obese individuals. Adjuvant immunotherapy extended PFS for patients receiving prior NCIT, whereas adjuvant chemotherapy delivered survival benefits to those with pathological lymph node metastasis. We constructed optimal treatment rule (OTR) decision trees with moderate‐to‐good predictive capacity to guide selection of neoadjuvant and adjuvant therapies based on survival benefit. These results highlight the necessity of precision perioperative therapy for ESCC. The established OTR decision trees can support individualized clinical decision‐making.
Open AccessAdvocating for Precision Neoadjuvant and Subsequent Adjuvant Therapies in Esophageal Squamous Cell Carcinoma: Evidence From a Real‐World Multicenter Study
Controversies persist regarding the optimal regimens of neoadjuvant and adjuvant therapies for locally advanced esophageal squamous cell carcinoma (ESCC). This real‐world cohort study aimed to compare the efficacy of neoadjuvant chemotherapy (NCT), chemoradiotherapy (NCRT), and chemoimmunotherapy (NCIT), and to clarify the survival contributions of adjuvant strategies. We retrospectively enrolled 1818 ESCC patients across four high‐volume Chinese medical centers. After propensity score matching, pathological tumor response and tumor downstaging followed the hierarchy NCRT > NCIT > NCT, yet no significant differences were detected in overall survival (OS) or progression‐free survival (PFS). Subgroup analyses revealed superior OS benefits of NCIT in never‑smokers, nondrinkers, and patients with clinical N2–3 disease compared with NCT. While NCRT showed greater PFS benefit than NCIT as clinical T stage advanced, its OS advantage was restricted to obese individuals. Adjuvant immunotherapy extended PFS for patients receiving prior NCIT, whereas adjuvant chemotherapy delivered survival benefits to those with pathological lymph node metastasis. We constructed optimal treatment rule (OTR) decision trees with moderate‐to‐good predictive capacity to guide selection of neoadjuvant and adjuvant therapies based on survival benefit. These results highlight the necessity of precision perioperative therapy for ESCC. The established OTR decision trees can support individualized clinical decision‐making.
- Open Access
- 16 July 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1831634
Highlighting sarcopenia management in cancer treatments: evidence from umbrella meta-analysis
Introduction: The role of sarcopenia in cancer treatment remains to be fully documented. This umbrella meta-analysis aimed to investigate the impact of sarcopenia on therapeutic outcomes across common malignancies with high incidence or mortality. Methods: We conducted an umbrella review of existing meta-analyses based on cohort studies. PubMed, Web of Science, and Embase were systematically searched from inception to October 2025. The primary endpoints were survival outcomes after surgical or first-line treatments. Supplementary meta-analyses were performed for outcomes with insufficient existing evidence. The systematic review protocol was registered in PROSPERO (CRD42022383726). Results: A total of 59 meta-analyses were included, comprising 49 from the literature search and 10 newly conducted in this study, covering 12 cancer types. In patients undergoing surgery, sarcopenia was significantly associated with shorter overall survival (HR = 1.59, 95% CI: 1.37–1.88) and disease-free survival (HR = 1.64, 95% CI: 1.39–1.93), as well as increased risks of any postoperative complications (OR = 1.48, 95% CI: 1.21–1.81) and major complications (OR = 1.51, 95% CI: 1.30–1.76). In patients receiving first-line non-surgical therapy, sarcopenia remained an independent risk factor for poorer overall survival (HR = 1.49, 95% CI: 1.39–1.61) and progression-free survival (HR = 1.39, 95% CI: 1.17–1.66). The methodological quality of included meta-analyses was generally high, while the GRADE certainty of evidence for most outcomes was rated as low or very low. Sarcopenia was also associated with inferior survival after cancer immunotherapy. Discussion: Sarcopenia is consistently associated with adverse therapeutic outcomes across multiple cancers and treatment modalities. It warrants attention in clinical management and represents a promising target for improving cancer therapeutic outcomes. Systematic review registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD42022383726.
- 16 July 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1831634
Open AccessHighlighting sarcopenia management in cancer treatments: evidence from umbrella meta-analysis
Introduction: The role of sarcopenia in cancer treatment remains to be fully documented. This umbrella meta-analysis aimed to investigate the impact of sarcopenia on therapeutic outcomes across common malignancies with high incidence or mortality. Methods: We conducted an umbrella review of existing meta-analyses based on cohort studies. PubMed, Web of Science, and Embase were systematically searched from inception to October 2025. The primary endpoints were survival outcomes after surgical or first-line treatments. Supplementary meta-analyses were performed for outcomes with insufficient existing evidence. The systematic review protocol was registered in PROSPERO (CRD42022383726). Results: A total of 59 meta-analyses were included, comprising 49 from the literature search and 10 newly conducted in this study, covering 12 cancer types. In patients undergoing surgery, sarcopenia was significantly associated with shorter overall survival (HR = 1.59, 95% CI: 1.37–1.88) and disease-free survival (HR = 1.64, 95% CI: 1.39–1.93), as well as increased risks of any postoperative complications (OR = 1.48, 95% CI: 1.21–1.81) and major complications (OR = 1.51, 95% CI: 1.30–1.76). In patients receiving first-line non-surgical therapy, sarcopenia remained an independent risk factor for poorer overall survival (HR = 1.49, 95% CI: 1.39–1.61) and progression-free survival (HR = 1.39, 95% CI: 1.17–1.66). The methodological quality of included meta-analyses was generally high, while the GRADE certainty of evidence for most outcomes was rated as low or very low. Sarcopenia was also associated with inferior survival after cancer immunotherapy. Discussion: Sarcopenia is consistently associated with adverse therapeutic outcomes across multiple cancers and treatment modalities. It warrants attention in clinical management and represents a promising target for improving cancer therapeutic outcomes. Systematic review registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD42022383726.
- 9 July 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 225, 105472
Neoadjuvant therapy for NSCLC: From monotherapy to precision combination therapy
- 9 July 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 225, 105472
Neoadjuvant therapy for NSCLC: From monotherapy to precision combination therapy
- Open Access
- 26 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1852863
Development and validation of a sepsis-specific systemic inflammation classification system for mortality prediction
Background: The role of nutrition and systemic inflammation in the prognosis of sepsis remains unclear. This study aimed to evaluate the predictive value of existing nutrition/inflammation-based indices for mortality in sepsis patients and to develop a sepsis-specific systemic inflammation classification (SSIC) system. Methods: Using the MIMIC-IV 3.0 database, we investigated and compared the predictive value of 18 nutrition/inflammation-based indices for mortality in sepsis patients admitted to the intensive care unit (ICU). These indices were calculated from biochemical tests and anthropometric measurements at ICU admission. The SSIC system was established by combining existing indices and validated in an independent institutional cohort. Results: Analysis of 11,577 sepsis patients from the MIMIC-IV 3.0 database revealed that seven of the 18 nutrition/inflammation-based indices had predictive value for in-hospital and in-ICU mortality, albeit with low discriminative ability. The neutrophil-to-lymphocyte ratio (NLR) and glucose-to-lymphocyte ratio (GLR), both of which focus on systemic inflammation, demonstrated the best predictive performance in both indirect and direct comparisons. The SSIC system, which combines NLR and GLR, classified systemic inflammation risk into low, moderate, and high categories. This system improved discriminative ability for mortality and showed consistent predictive value across different subpopulations. Moreover, adding the SSIC system to existing severity scores enhanced their discriminative performance for sepsis mortality. The utility of the SSIC system was validated in an independent institutional cohort of 496 sepsis patients. Conclusion: This study confirmed the predictive value of 18 nutrition/inflammation-based indices for mortality in sepsis patients. The SSIC system was established and validated as a tool for mortality risk stratification and may be considered for further evaluation alongside established severity scores.
- 26 June 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1852863
Open AccessDevelopment and validation of a sepsis-specific systemic inflammation classification system for mortality prediction
Background: The role of nutrition and systemic inflammation in the prognosis of sepsis remains unclear. This study aimed to evaluate the predictive value of existing nutrition/inflammation-based indices for mortality in sepsis patients and to develop a sepsis-specific systemic inflammation classification (SSIC) system. Methods: Using the MIMIC-IV 3.0 database, we investigated and compared the predictive value of 18 nutrition/inflammation-based indices for mortality in sepsis patients admitted to the intensive care unit (ICU). These indices were calculated from biochemical tests and anthropometric measurements at ICU admission. The SSIC system was established by combining existing indices and validated in an independent institutional cohort. Results: Analysis of 11,577 sepsis patients from the MIMIC-IV 3.0 database revealed that seven of the 18 nutrition/inflammation-based indices had predictive value for in-hospital and in-ICU mortality, albeit with low discriminative ability. The neutrophil-to-lymphocyte ratio (NLR) and glucose-to-lymphocyte ratio (GLR), both of which focus on systemic inflammation, demonstrated the best predictive performance in both indirect and direct comparisons. The SSIC system, which combines NLR and GLR, classified systemic inflammation risk into low, moderate, and high categories. This system improved discriminative ability for mortality and showed consistent predictive value across different subpopulations. Moreover, adding the SSIC system to existing severity scores enhanced their discriminative performance for sepsis mortality. The utility of the SSIC system was validated in an independent institutional cohort of 496 sepsis patients. Conclusion: This study confirmed the predictive value of 18 nutrition/inflammation-based indices for mortality in sepsis patients. The SSIC system was established and validated as a tool for mortality risk stratification and may be considered for further evaluation alongside established severity scores.
- Open Access
- 12 June 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1865456
Standardized sarcopenia assessment should be incorporated into prognosis analysis of esophageal cancers: a prospective cohort study lasting 8 years
Background: The prognosis value of preoperative sarcopenia in esophageal cancer patients undergoing surgical resection have rarely been prospectively investigated. The necessity of a standardized sarcopenia assessment—including muscle mass, muscle strength, and physical performance—has not been tested. Methods: This prospective cohort study assessed the appendicular skeletal muscle mass index (ASMI), handgrip strength, and gait speed to classify participants as normal, pre-sarcopenia, or sarcopenia. The prognostic value of sarcopenia for overall survival (OS) and disease-free survival (DFS) was evaluated using propensity score matching, multivariable analysis, and subgroup analysis. The additive contribution of each muscle criterion to survival prediction was assessed using SHapley Additive exPlanations. Results: This study included 212 participants, with a median survivor follow-up of 91.8 months. Sarcopenia risk, including both pre-sarcopenia and sarcopenia, was identified as an independent prognostic factor for poor OS and DFS. These prognostic values remained significant across almost all patient subgroups. Incorporating the sarcopenia classification system into nomograms based on clinical cancer stage improved prediction efficacy for both OS and DFS. Additionally, although the three dimensions of muscle assessment were independently associated with OS and DFS, gait speed showed the largest contribution to survival prediction, while ASMI and handgrip strength showed comparably slightly inferior contributions. Conclusion: Sarcopenia assessment is recommended for incorporation into the prognosis analysis of surgically treated esophageal cancer patients. Comprehensive assessment of muscle mass, muscle strength, and physical performance is necessary for definitive diagnosis, severity classification, and effective prediction. Trial registration: Identifier, ChiCTR 1,800,017,792.
- 12 June 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1865456
Open AccessStandardized sarcopenia assessment should be incorporated into prognosis analysis of esophageal cancers: a prospective cohort study lasting 8 years
Background: The prognosis value of preoperative sarcopenia in esophageal cancer patients undergoing surgical resection have rarely been prospectively investigated. The necessity of a standardized sarcopenia assessment—including muscle mass, muscle strength, and physical performance—has not been tested. Methods: This prospective cohort study assessed the appendicular skeletal muscle mass index (ASMI), handgrip strength, and gait speed to classify participants as normal, pre-sarcopenia, or sarcopenia. The prognostic value of sarcopenia for overall survival (OS) and disease-free survival (DFS) was evaluated using propensity score matching, multivariable analysis, and subgroup analysis. The additive contribution of each muscle criterion to survival prediction was assessed using SHapley Additive exPlanations. Results: This study included 212 participants, with a median survivor follow-up of 91.8 months. Sarcopenia risk, including both pre-sarcopenia and sarcopenia, was identified as an independent prognostic factor for poor OS and DFS. These prognostic values remained significant across almost all patient subgroups. Incorporating the sarcopenia classification system into nomograms based on clinical cancer stage improved prediction efficacy for both OS and DFS. Additionally, although the three dimensions of muscle assessment were independently associated with OS and DFS, gait speed showed the largest contribution to survival prediction, while ASMI and handgrip strength showed comparably slightly inferior contributions. Conclusion: Sarcopenia assessment is recommended for incorporation into the prognosis analysis of surgically treated esophageal cancer patients. Comprehensive assessment of muscle mass, muscle strength, and physical performance is necessary for definitive diagnosis, severity classification, and effective prediction. Trial registration: Identifier, ChiCTR 1,800,017,792.
- Open Access
- 24 February 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-18
Development and validation of the systemic nutrition/inflammation index for improving perioperative management of non-small cell lung cancer
Systemic nutrition and inflammation status is recognized for its influence on cancer survival, yet its role in perioperative outcomes remains poorly defined. This study aimed to refine the assessment of systemic nutrition and inflammation status in non-small cell lung cancer (NSCLC) patients and to elucidate its impact on perioperative outcomes. All patients underwent video-assisted thoracoscopic lobectomy, with their nutrition and inflammation status assessed based on preoperative blood tests. The development cohort, comprising 1497 NSCLC patients from two centers, evaluated the predictive value of systemic nutrition/inflammation indicators for perioperative endpoints and formulated the systemic nutrition-inflammation index (SNII). The tertiles of SNII were used to classify the nutrition/inflammation risk as high (< 15.6), moderate (15.6–23.1), and low (> 23.1). An external validation cohort of 505 NSCLC patients was utilized to confirm the effectiveness of SNII in guiding perioperative management. In the development cohort, the SNII tool, calculated as the product of total cholesterol and total lymphocytes divided by total monocytes, demonstrated a stronger correlation with perioperative outcomes compared to 11 existing nutrition/inflammation indicators. A low SNII score, indicative of high nutrition/inflammation risk, was independently predictive of increased complication incidence and severity, as well as prolonged chest tube duration and hospital stay. These findings were corroborated in the validation cohort. Upon combining the development and validation cohorts, the superiority of the SNII in predicting perioperative outcomes was further confirmed over the existing nutrition/inflammation indicators. Additionally, comprehensive subgroup analyses revealed the moderately variable efficacy of SNII across different patient populations. This study developed and validated the SNII as a tool for identifying systemic nutrition and inflammation risk, which can enhance perioperative managements in NSCLC patients. Patients identified with high risk may benefit from prehabilitation and intensive treatments, highlighting the need for further research.
- 24 February 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-18
Open AccessDevelopment and validation of the systemic nutrition/inflammation index for improving perioperative management of non-small cell lung cancer
Systemic nutrition and inflammation status is recognized for its influence on cancer survival, yet its role in perioperative outcomes remains poorly defined. This study aimed to refine the assessment of systemic nutrition and inflammation status in non-small cell lung cancer (NSCLC) patients and to elucidate its impact on perioperative outcomes. All patients underwent video-assisted thoracoscopic lobectomy, with their nutrition and inflammation status assessed based on preoperative blood tests. The development cohort, comprising 1497 NSCLC patients from two centers, evaluated the predictive value of systemic nutrition/inflammation indicators for perioperative endpoints and formulated the systemic nutrition-inflammation index (SNII). The tertiles of SNII were used to classify the nutrition/inflammation risk as high (< 15.6), moderate (15.6–23.1), and low (> 23.1). An external validation cohort of 505 NSCLC patients was utilized to confirm the effectiveness of SNII in guiding perioperative management. In the development cohort, the SNII tool, calculated as the product of total cholesterol and total lymphocytes divided by total monocytes, demonstrated a stronger correlation with perioperative outcomes compared to 11 existing nutrition/inflammation indicators. A low SNII score, indicative of high nutrition/inflammation risk, was independently predictive of increased complication incidence and severity, as well as prolonged chest tube duration and hospital stay. These findings were corroborated in the validation cohort. Upon combining the development and validation cohorts, the superiority of the SNII in predicting perioperative outcomes was further confirmed over the existing nutrition/inflammation indicators. Additionally, comprehensive subgroup analyses revealed the moderately variable efficacy of SNII across different patient populations. This study developed and validated the SNII as a tool for identifying systemic nutrition and inflammation risk, which can enhance perioperative managements in NSCLC patients. Patients identified with high risk may benefit from prehabilitation and intensive treatments, highlighting the need for further research.
- Open Access
- 2 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 45 (2) , 110-137
Nicotinamide N‐methyltransferase negatively regulates metastasis‐promoting property of cancer‐associated fibroblasts in lung adenocarcinoma
Background: Recurrence and metastasis remain significant challenges in lung adenocarcinoma (LUAD) after radical resection. The mechanisms behind the recurrence and metastasis of LUAD remain elusive, and deregulated cellular metabolism is suspected to play a significant role. This study explores the metabolic and epigenetic regulation mediated by nicotinamide N‐methyl transferase (NNMT) in LUAD. Methods: Untargeted metabolomic analyses were performed to detect metabolism irregularities. Single‐cell RNA sequencing (RNA‐seq) databases and multiplex immunofluorescence analysis were used to identify the location of NNMT within the tumor microenvironment. The biological functions of NNMT were investigated both in vitro and in vivo, with RNA‐seq and chromatin immunoprecipitation‐PCR providing insights into underlying mechanisms. Finally, single‐cell RNA‐seq data and immunohistochemistry of primary tumors were analyzed to validate the main findings. Results: Untargeted metabolomic analyses revealed metabolic aberrations in amino acids, organic acids, lipids, and nicotinamide pathways, which are linked to metastasis of non‐small cell lung cancer. NNMT is a key enzyme in nicotinamide metabolism, and we found the bulk tissue mRNA level of NNMT gene was inversely associated with LUAD metastasis. NNMT was proved to be predominantly expressed in cancer‐associated fibroblasts (CAFs) within the stromal regions of LUAD, and a low stromal NNMT expression was identified as a predictor of poor disease‐free survival following radical resection of LUAD. The isolation and primary culture of CAFs from LUAD enabled in vitro and in vivo experiments, which confirmed that NNMT negatively regulated the metastasis‐promoting properties of CAFs in LUAD. Mechanistically, the downregulation of NNMT led to an increase in intracellular methyl groups by reducing the activity of the methionine cycle, resulting in heightened methylation at H3K4me3. This alteration triggered the upregulation of genes involved in extracellular matrix remodeling in CAFs, including those encoding collagens, integrins, laminins, and matrix metalloproteinases, thereby facilitating cancer cell invasion and metastasis. Reanalysis of single‐cell RNA‐seq data and immunohistochemistry assays of primary LUAD tissues substantiated NNMT's negative regulation of these genes in CAFs. Conclusions: This study provides novel insights into the metabolic and epigenetic regulatory functions of NNMT in CAFs, expanding the current understanding of LUAD metastasis regulation and suggesting potential avenues for future research and therapeutic development.
- 2 December 2024
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 45 (2) , 110-137
Open AccessNicotinamide N‐methyltransferase negatively regulates metastasis‐promoting property of cancer‐associated fibroblasts in lung adenocarcinoma
Background: Recurrence and metastasis remain significant challenges in lung adenocarcinoma (LUAD) after radical resection. The mechanisms behind the recurrence and metastasis of LUAD remain elusive, and deregulated cellular metabolism is suspected to play a significant role. This study explores the metabolic and epigenetic regulation mediated by nicotinamide N‐methyl transferase (NNMT) in LUAD. Methods: Untargeted metabolomic analyses were performed to detect metabolism irregularities. Single‐cell RNA sequencing (RNA‐seq) databases and multiplex immunofluorescence analysis were used to identify the location of NNMT within the tumor microenvironment. The biological functions of NNMT were investigated both in vitro and in vivo, with RNA‐seq and chromatin immunoprecipitation‐PCR providing insights into underlying mechanisms. Finally, single‐cell RNA‐seq data and immunohistochemistry of primary tumors were analyzed to validate the main findings. Results: Untargeted metabolomic analyses revealed metabolic aberrations in amino acids, organic acids, lipids, and nicotinamide pathways, which are linked to metastasis of non‐small cell lung cancer. NNMT is a key enzyme in nicotinamide metabolism, and we found the bulk tissue mRNA level of NNMT gene was inversely associated with LUAD metastasis. NNMT was proved to be predominantly expressed in cancer‐associated fibroblasts (CAFs) within the stromal regions of LUAD, and a low stromal NNMT expression was identified as a predictor of poor disease‐free survival following radical resection of LUAD. The isolation and primary culture of CAFs from LUAD enabled in vitro and in vivo experiments, which confirmed that NNMT negatively regulated the metastasis‐promoting properties of CAFs in LUAD. Mechanistically, the downregulation of NNMT led to an increase in intracellular methyl groups by reducing the activity of the methionine cycle, resulting in heightened methylation at H3K4me3. This alteration triggered the upregulation of genes involved in extracellular matrix remodeling in CAFs, including those encoding collagens, integrins, laminins, and matrix metalloproteinases, thereby facilitating cancer cell invasion and metastasis. Reanalysis of single‐cell RNA‐seq data and immunohistochemistry assays of primary LUAD tissues substantiated NNMT's negative regulation of these genes in CAFs. Conclusions: This study provides novel insights into the metabolic and epigenetic regulatory functions of NNMT in CAFs, expanding the current understanding of LUAD metastasis regulation and suggesting potential avenues for future research and therapeutic development.
- 8 July 2024
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 17 (3) , 503-525
Unveiling the detrimental vicious cycle linking skeletal muscle and COVID‐19: A systematic review and meta‐analysis
Objective: Skeletal muscle catabolism supports multiple organs and systems during severe trauma and infection, but its role in COVID‐19 remains unclear. This study investigates the interactions between skeletal muscle and COVID‐19.Methods: The PubMed, EMbase, and The Cochrane Library databases were systematically searched from January 2020 to August 2023 for cohort studies focusing on the impact of skeletal muscle on COVID‐19 prevalence and outcomes, and longitudinal studies examining skeletal muscle changes caused by COVID‐19. Skeletal muscle quantity (SMQN) and quality (SMQL) were assessed separately. The random‐effect model was predominantly utilized for statistical analysis.Results: Seventy studies with moderate to high quality were included. Low SMQN/SMQL was associated with an increased risk of COVID‐19 infection (OR = 1.62, p < 0.001). Both the low SMQN and SMQL predicted COVID‐19‐related mortality (OR = 1.53, p = 0.016; OR = 2.18, p = 0.001, respectively). Mortality risk decreased with increasing SMQN (OR = 0.979, p = 0.009) and SMQL (OR = 0.972, p = 0.034). Low SMQN and SMQL were also linked to the need for intensive care unit/mechanical ventilation, increased COVID‐19 severity, and longer hospital stays. Significant skeletal muscle wasting, characterized by reduced volume and strength, was observed during COVID‐19 infection and the pandemic.Conclusions: This study reveals a detrimental vicious circle between skeletal muscle and COVID‐19. Effective management of skeletal muscle could be beneficial for treating COVID‐19 infections and addressing the broader pandemic. These findings have important implications for the management of future virus pandemics.Systematic review registration: PROSPERO CRD42023395476.
- 8 July 2024
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 17 (3) , 503-525
Unveiling the detrimental vicious cycle linking skeletal muscle and COVID‐19: A systematic review and meta‐analysis
Objective: Skeletal muscle catabolism supports multiple organs and systems during severe trauma and infection, but its role in COVID‐19 remains unclear. This study investigates the interactions between skeletal muscle and COVID‐19.Methods: The PubMed, EMbase, and The Cochrane Library databases were systematically searched from January 2020 to August 2023 for cohort studies focusing on the impact of skeletal muscle on COVID‐19 prevalence and outcomes, and longitudinal studies examining skeletal muscle changes caused by COVID‐19. Skeletal muscle quantity (SMQN) and quality (SMQL) were assessed separately. The random‐effect model was predominantly utilized for statistical analysis.Results: Seventy studies with moderate to high quality were included. Low SMQN/SMQL was associated with an increased risk of COVID‐19 infection (OR = 1.62, p < 0.001). Both the low SMQN and SMQL predicted COVID‐19‐related mortality (OR = 1.53, p = 0.016; OR = 2.18, p = 0.001, respectively). Mortality risk decreased with increasing SMQN (OR = 0.979, p = 0.009) and SMQL (OR = 0.972, p = 0.034). Low SMQN and SMQL were also linked to the need for intensive care unit/mechanical ventilation, increased COVID‐19 severity, and longer hospital stays. Significant skeletal muscle wasting, characterized by reduced volume and strength, was observed during COVID‐19 infection and the pandemic.Conclusions: This study reveals a detrimental vicious circle between skeletal muscle and COVID‐19. Effective management of skeletal muscle could be beneficial for treating COVID‐19 infections and addressing the broader pandemic. These findings have important implications for the management of future virus pandemics.Systematic review registration: PROSPERO CRD42023395476.